Progress, Potential, and Possibilities Podcast / Show · 2026-07-07 · 48 min
Send us Fan Mail What if radiation could become one of the most precise medicines ever invented? Long before radiopharmaceuticals became one of the hottest areas in biotech, today's guest was helping pioneer targeted radiation therapies that seek out cancer cells while minimizing damage to healthy tissue. Today, the field is attracting billions in investment and reshaping oncology. Our guest today is one of the true pioneers of modern targeted radiopharmaceutical therapy. Dr. Ebrahim Delpassand, MD is the Founder, Chairman and CEO of RadioMedix ( ), a clinical-stage biotechnology company developing next-generation targeted radioactive diagnostics and therapeutics for cancer. Long before radiopharmaceuticals became one of the most exciting areas in precision oncology, Dr. Delpassand was introducing these therapies to patients who had exhausted every other option. As former Deputy Chairman and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center, Dr.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
How Targeted Radiotherapy Is Changing Cancer Care w/ John Babich, President, CSO, Ratio TherapeuticsCareTalk: Healthcare. Unfiltered. · on Oncology94 / 100
How AI is Transforming Cancer Care with Amber Simpson | Approximately Correct PodcastApproximately Correct: An AI Podcast from Amii · on Precision medicine91 / 100
How Healthcare Moves from Reactive Care to Preventive with Ray PawlickiBiology Matters · on Precision medicine83 / 100
AstraZeneca's CFO on GLP-1 Drugs, AI, and MoreAt Barron's · on Oncology78 / 100
US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into GrowthPwC's Next in Health · on Oncology76 / 100
Healthcare AI Is Failing And the Fix Isn't More DataSaaS That App · on Precision medicine73 / 100Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-ColtonReversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart InstituteThe Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen